NCCN Guidelines and Compendium Updated
NCCN Flash Updates™ sent February 6, 2013
NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Adult Cancer Pain. These NCCN Guidelines® are currently available as Version 1.2013.
- Principles of Cancer Pain Management
- Three new principles were added:
- Goals of pain management are improved comfort and function.
- Persistent cancer pain often requires treatment with regularly scheduled analgesics, and supplemental doses of analgesics are often required to manage breakthrough pain.
- Optimize integrative interventions
- Opioids and Risk Evaluation and Mitigation Strategy (REMS)
- A revision was made to the following statement: "REMS programs are currently in place for all transmucosal fentanyl products, transdermal fentanyl products, transdermal buprenorphine (See Approved Risk Evaluation and Mitigation Strategies [REMS]), and in 2013 the FDA will introduce REMS starting with continuing education for morphine-naltrexone combination product, all extended-release opioids, and long-acting opioids (methadone). See FDA Questions and Answers for REMS for Extended-Release and Long-Acting Opioid Analgesics."
- Miscellaneous Analgesics
- A new page titled, "Miscellaneous analgesics" was added for tramadol, transdermal buprenorphine, and ketamine.
- Non-Opioid Analgesics
- The dosing of acetaminophen was clarified by adding: "Acetaminophen, 650 mg every 4 h or 1 g every 6 h (daily maximum 4 g/d) in adult patients with normal liver function."
For the complete updated versions of the NCCN Guidelines® and the NCCN Compendium®, please visit NCCN.org.
To view the NCCN Guidelines for Patients®, please visit NCCN.com.
To access free NCCN Guidelines mobile apps for iPhone and Android, visit NCCN.org/mobile.
Now Available! The Virtual Library of NCCN Guidelines are now formatted for iPad and Android. Visit NCCN.org/mobile/tablet.asp.